OBJECTIVE: Familial combined hyperlipidemia (FCHL) is a genetically complex lipid disorder that is diagnosed in families by combinations of increased cholesterol, triglycerides, and/or apolipoprotein B (apoB) levels in patients and their first-degree relatives. Identifying the predisposing genes promises to reveal the primary risk factors and susceptibility pathways and suggest methods of prevention and treatment. As with most genetically complex disorders, a clinical definition of disease may not be the most useful phenotype for finding the complement of predisposing genes, and the quantitative traits used to define the disorder can provide important information. This is a report of a quantitative trait loci (QTL) analysis of FCHL. METHODS AND RESULTS: A full genome scan of 377 multi-allelic markers genotyped at approximately 10 centimorgan (cM) intervals was conducted in 150 sibling pairs from 22 nuclear families in FCHL pedigrees. These data were analyzed by 2 multipoint QTL linkage methods using the nonparametric and Haseman-Elston procedures of the Genehunter software. Using a criterion of P<0.001 by the nonparametric analysis, we found evidence of 2 apoB QTL at 1p21-31 (P<0.000009) and 17p11-q21 (P<0.000009), a total serum cholesterol QTL at 12p13 (P<0.0001), and a serum triglycerides QTL at 4p15-16 (P<0.0002). Using the criterion of P<0.03 for at least 2 traits at the same locus, additional evidence for cholesterol (P<0.01) and a triglycerides P<0.02) was observed at 17p11-21, as well as suggestive evidence for apoB (P<0.02) and triglycerides (P<0.01) at 4q34-35, and cholesterol (P<0.01) and triglycerides (P<0.02) and a binary FCHL trait (lod=1.5) at 16p12-13. CONCLUSIONS: QTL analyses of the traits that define FCHL are effective for localizing disease-predisposing genes.
OBJECTIVE: Familial combined hyperlipidemia (FCHL) is a genetically complex lipid disorder that is diagnosed in families by combinations of increased cholesterol, triglycerides, and/or apolipoprotein B (apoB) levels in patients and their first-degree relatives. Identifying the predisposing genes promises to reveal the primary risk factors and susceptibility pathways and suggest methods of prevention and treatment. As with most genetically complex disorders, a clinical definition of disease may not be the most useful phenotype for finding the complement of predisposing genes, and the quantitative traits used to define the disorder can provide important information. This is a report of a quantitative trait loci (QTL) analysis of FCHL. METHODS AND RESULTS: A full genome scan of 377 multi-allelic markers genotyped at approximately 10 centimorgan (cM) intervals was conducted in 150 sibling pairs from 22 nuclear families in FCHL pedigrees. These data were analyzed by 2 multipoint QTL linkage methods using the nonparametric and Haseman-Elston procedures of the Genehunter software. Using a criterion of P<0.001 by the nonparametric analysis, we found evidence of 2 apoB QTL at 1p21-31 (P<0.000009) and 17p11-q21 (P<0.000009), a total serum cholesterol QTL at 12p13 (P<0.0001), and a serum triglycerides QTL at 4p15-16 (P<0.0002). Using the criterion of P<0.03 for at least 2 traits at the same locus, additional evidence for cholesterol (P<0.01) and a triglycerides P<0.02) was observed at 17p11-21, as well as suggestive evidence for apoB (P<0.02) and triglycerides (P<0.01) at 4q34-35, and cholesterol (P<0.01) and triglycerides (P<0.02) and a binary FCHL trait (lod=1.5) at 16p12-13. CONCLUSIONS: QTL analyses of the traits that define FCHL are effective for localizing disease-predisposing genes.
Authors: Ellen M Wijsman; Joseph H Rothstein; Robert P Igo; John D Brunzell; Arno G Motulsky; Gail P Jarvik Journal: Hum Genet Date: 2010-04-11 Impact factor: 4.132
Authors: G Andersen; J Overgaard; A Albrechtsen; C Glümer; K Borch-Johnsen; T Jørgensen; T Hansen; O Pedersen Journal: Diabetologia Date: 2005-11-12 Impact factor: 10.122
Authors: Daphna Weissglas-Volkov; Christopher L Plaisier; Adriana Huertas-Vazquez; Ivette Cruz-Bautista; Daniela Riaño-Barros; Miguel Herrera-Hernandez; Laura Riba; Rita M Cantor; Janet S Sinsheimer; Carlos A Aguilar-Salinas; Teresa Tusie-Luna; Päivi Pajukanta Journal: Arterioscler Thromb Vasc Biol Date: 2009-12-03 Impact factor: 8.311
Authors: Jenny C Lee; Daphna Weissglas-Volkov; Mira Kyttälä; Zari Dastani; Rita M Cantor; Eric M Sobel; Christopher L Plaisier; James C Engert; Marleen M J van Greevenbroek; John P Kane; Mary J Malloy; Clive R Pullinger; Adriana Huertas-Vazquez; Carlos A Aguilar-Salinas; Teresa Tusie-Luna; Tjerk W A de Bruin; Bradley E Aouizerat; Carla C J van der Kallen; Carlo M Croce; Rami I Aqeilan; Michel Marcil; Jorma S A Viikari; Terho Lehtimäki; Olli T Raitakari; Johanna Kuusisto; Markku Laakso; Marja-Riitta Taskinen; Jacques Genest; Päivi Pajukanta Journal: Am J Hum Genet Date: 2008-08 Impact factor: 11.025
Authors: Sara Bretschger Seidelmann; Lin Li; Gong-Qing Shen; Eric J Topol; Qing Kenneth Wang Journal: J Lipid Res Date: 2008-01-31 Impact factor: 5.922
Authors: Martin Farrall; Fiona R Green; John F Peden; Per G Olsson; Robert Clarke; Mai-Lis Hellenius; Stephan Rust; Jacob Lagercrantz; Maria Grazia Franzosi; Helmut Schulte; Alisoun Carey; Gunnar Olsson; Gerd Assmann; Gianni Tognoni; Rory Collins; Anders Hamsten; Hugh Watkins Journal: PLoS Genet Date: 2006-05-19 Impact factor: 5.917